J&J settles with two Ohio counties ahead of upcoming opioid trial

2 October 2019

US healthcare giant Johnson & Johnson (NYSE: JNJ) and its Janssen Pharmaceutical Companies yesterday announced a $20.4 million settlement agreement with the Ohio counties of Cuyahoga and Summit that resolves all of the counties’ claims with no admission of liability and removes the company from the bellwether federal trial against drugmakers blamed for the US opioid crisis scheduled to begin October 21, 2019.

As part of the agreement, the company will make a combined $10 million settlement payment to the counties.

J&J became the fourth drugmaker to settle claims ahead of the Federal Court trial later this month. Mallinckrodt finalised a $24 million settlement with the same two counties on Monday. Endo International and Allergan also settled with the two counties in August to avoid going to trial.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK